S. Mousavi, F. Hayati, Shokouh Shayanpour, S. A. Halili
{"title":"终末期肾病患者的镁和甲状旁腺激素","authors":"S. Mousavi, F. Hayati, Shokouh Shayanpour, S. A. Halili","doi":"10.15171/JPD.2018.22","DOIUrl":null,"url":null,"abstract":"Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"50 1","pages":"72-73"},"PeriodicalIF":0.0000,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Magnesium and parathyroid hormone among end-stage renal disease patients\",\"authors\":\"S. Mousavi, F. Hayati, Shokouh Shayanpour, S. A. Halili\",\"doi\":\"10.15171/JPD.2018.22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.\",\"PeriodicalId\":16657,\"journal\":{\"name\":\"Journal of Parathyroid Disease\",\"volume\":\"50 1\",\"pages\":\"72-73\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Parathyroid Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15171/JPD.2018.22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Parathyroid Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15171/JPD.2018.22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Magnesium and parathyroid hormone among end-stage renal disease patients
Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
